# LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Sitagliptin** (DPP-4 inhibitors)
- Comparator (class): **Semaglutide** (GLP-1 Receptor Agonists)
- Outcome: **Genitourinary infection**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	211,683	158,911	4,323	27.20
Merative CCAE	7,317	4,488	182	40.55
Merative MDCD	-	-	-	-
Merative MDCR	1,946	1,013	73	72.08
Optum Clinformatics	4,113	2,314	154	66.56
Optum EHR	21,879	9,972	410	41.11
Veterans Affairs	54	17	0	0.00

How Reliable Are the Effect Estimates? (Objective diagnostics)

What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)